Scholar Rock/$SRRK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Scholar Rock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
- Ticker
- $SRRK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 289
- Headquarters
- Cambridge, United States
- Website
- www.scholarrock.com
Scholar Rock Metrics
BasicAdvanced
$5.2B
-
-$3.36
0.68
-
Price and volume
Market cap
$5.2B
Beta
0.68
52-week high
$61.76
52-week low
$27.07
Average daily volume
1.8M
Financial strength
Current ratio
7.021
Quick ratio
6.839
Long term debt to equity
0.778
Total debt to equity
0.778
Interest coverage (TTM)
-38.02%
Profitability
EBITDA (TTM)
-404.883
Management effectiveness
Return on assets (TTM)
-58.82%
Return on equity (TTM)
-167.77%
Valuation
Price to book
20.56
Price to tangible book (TTM)
20.56
Price to free cash flow (TTM)
-17.568
Free cash flow yield (TTM)
-5.69%
Free cash flow per share (TTM)
-2.443
Growth
Earnings per share change (TTM)
2.18%
3-year earnings per share growth (CAGR)
5.05%
What the Analysts think about Scholar Rock
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Analyst projections of the future price of Scholar Rock stock.
Bulls say / Bears say
The FDA approved ISEMBYLD for adults and children aged two and over with SMA who are on SMN2-targeted treatment. In its pivotal trial, the recommended dose improved motor-function scores by 2.2 points versus placebo, giving Scholar Rock its first commercial product and a differentiated add-on treatment. (Scholar Rock)
Scholar Rock is extending its myostatin programme beyond SMA: its Phase 2 FORGE trial is testing apitegromab in FSHD, while SRK-439 is in a Phase 1 study. Success could open further uses for the company’s muscle-targeting approach. (Scholar Rock)
The company had $492 million in cash and marketable securities at June 30, and FDA approval made a further $150 million loan tranche available. The FDA has also awarded it a rare paediatric disease priority review voucher, giving Scholar Rock another potential source of funding as it builds the launch and develops its pipeline. (Scholar Rock, Federal Register)
Fractures occurred in 9% of patients on the recommended dose versus 2% on placebo. The FDA requires fracture cases to be reported as alerts and a pregnancy safety study, which could keep safety under close scrutiny after launch. (Scholar Rock, SEC)
Early uptake may be slowed by monthly infusions, prior-authorisation requirements and treatment-centre formulary decisions. Management expected access friction in the first few quarters, so the broad FDA label may not translate quickly into sales. (Investing.com)
European expansion faces a separate regulatory and manufacturing hurdle: Scholar Rock withdrew its European application and said it would resubmit it with an alternative manufacturing site. That leaves the timing of approval and sales outside the US uncertain. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
Scholar Rock Financial Performance
Revenues and expenses
Scholar Rock Earnings Performance
Company profitability
Upcoming events
No upcoming events
Scholar Rock News
AllArticlesVideos
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire3 weeks ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 month ago
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
Benzinga2 months ago
Funds containing Scholar Rock
AllUSDEURGBP
Fund name | Fund size | $SRRK weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.34% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.34% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.16% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.16% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.